TO STUDY THE EFFECTIVENESS OF INTRALESIONAL MEASLES MUMPS RUBELLA VACCINE AND VIT D3 FOR THE TREATMENT OF WARTS
Not Applicable
- Conditions
- Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
- Registration Number
- CTRI/2020/09/027933
- Lead Sponsor
- Dr Trisha Patel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with clinically confirmed cases of all type of warts in age groups >2 years and <70 years included in the study.
Exclusion Criteria
1) Immunocompromised patient such as patient taking anticancer drug, immunosuppressive drugs, steroids.
2) Patients with clinical history of immunosuppression.
3) Pregnant female (Married females in reproductive age group are excluded by UPT) and Lactating females, patient with generalized eczema, infective dermatosis, and patient with known hypersensitivity to Vit-D3 or MMR immunotherapy
4) Any acute illness/ acute febrile illness
5) Children less than 2 years
6) Patients with inflamed warts
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Partial or complete resolution of the viral warts in majority of the casesTimepoint: The patient will be evaluated at the beginning of study and then at interval of 21 days for 4 time. After that patient will be followed up at the interval of 3 and 6 months to see for recurrence.
- Secondary Outcome Measures
Name Time Method We will be able to evaluate the process of regression of the viral wartTimepoint: we will have an evaluation of disease activity at every 21 days and see for recurrence at the end of 6 months after the last injection